Collegium Pharmaceutical reported first-quarter 2026 revenue of $193.5 million [1], representing a nearly nine percent increase compared to the previous year [2].
This growth signals the company's successful diversification into the ADHD market, reducing its historical reliance on pain-management products while maintaining a steady core portfolio.
The company posted a quarterly profit of $14.5 million [3]. Financial results included a GAAP net income per share of $0.40 [4] and adjusted earnings per share of $1.76 [5].
A primary driver of the company's performance was the JORNAY PM ADHD franchise. The drug generated $38.9 million in quarterly net revenue [7], which is a 36 percent increase year-over-year [8].
Collegium provided product revenue guidance for the full year of 2026 ranging from $805 million to $825 million [9]. The midpoint of this full-year revenue guidance is $815 million [3].
The company is also projecting that JORNAY PM will generate between $190 million and $200 million in revenue throughout 2026 [10].
Beyond its current financial metrics, the company reported progress toward the planned acquisition of AZSTARYS. This move is part of a broader strategy to advance the company's pain portfolio alongside its growing ADHD business.
Executives shared these updates via a webcast earnings call from the company's headquarters in Stoughton, Massachusetts.
“Quarterly revenue of $193.5 million [1]”
Collegium's financial results demonstrate a strategic pivot toward ADHD treatments to balance its revenue streams. The significant growth of JORNAY PM suggests that the company is successfully capturing market share in a high-demand therapeutic area, which provides a financial cushion as it seeks to expand its pain-management portfolio through the acquisition of AZSTARYS.
